SE454746B - Neringskomposition som utgor en vattenlosning innehallande fran 1 till 20 viktprocent av minst tva oligopeptider, valda bland dipeptider och tripeptider - Google Patents

Neringskomposition som utgor en vattenlosning innehallande fran 1 till 20 viktprocent av minst tva oligopeptider, valda bland dipeptider och tripeptider

Info

Publication number: SE454746B
Authority: SE; Sweden
Prior art keywords: glycine; oligopeptides; tripeptides; composition according; dipeptides
Prior art date: 1980-03-14

Application number

SE8101585A

Other languages

English (en)

Swedish (sv)

Other versions

SE8101585L (sv

Inventor

S A Adibi

Original Assignee

Montefiore Hospital Ass

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1980-03-14

Filing date

1981-03-12

Publication date

1988-05-30

1981-03-12 Application filed by Montefiore Hospital Ass filed Critical Montefiore Hospital Ass

1981-09-15 Publication of SE8101585L publication Critical patent/SE8101585L/

1988-05-30 Publication of SE454746B publication Critical patent/SE454746B/sv

Links

108010038807 Oligopeptides Proteins 0.000 title claims description 45
102000015636 Oligopeptides Human genes 0.000 title claims description 45
239000000203 mixture Substances 0.000 title claims description 27
108010016626 Dipeptides Proteins 0.000 title claims description 15
235000016709 nutrition Nutrition 0.000 title claims description 7
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title description 3
125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims description 11
239000007864 aqueous solution Substances 0.000 claims description 10
235000020776 essential amino acid Nutrition 0.000 claims description 8
239000003797 essential amino acid Substances 0.000 claims description 8
229920005862 polyol Polymers 0.000 claims description 8
150000003077 polyols Chemical class 0.000 claims description 8
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 7
239000008103 glucose Substances 0.000 claims description 7
125000000539 amino acid group Chemical group 0.000 claims description 5
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 4
125000000729 N-terminal amino-acid group Chemical group 0.000 claims description 4
239000003925 fat Substances 0.000 claims description 4
229910052500 inorganic mineral Inorganic materials 0.000 claims description 4
235000010755 mineral Nutrition 0.000 claims description 4
239000011707 mineral Substances 0.000 claims description 4
235000013619 trace mineral Nutrition 0.000 claims description 4
239000011573 trace mineral Substances 0.000 claims description 4
235000013343 vitamin Nutrition 0.000 claims description 4
239000011782 vitamin Substances 0.000 claims description 4
229940088594 vitamin Drugs 0.000 claims description 4
229930003231 vitamin Natural products 0.000 claims description 4
YWEKFRWGKMPCEU-MDTVQASCSA-N 2-aminoacetic acid;(2s)-2-amino-4-methylpentanoic acid Chemical compound NCC(O)=O.CC(C)C[C@H](N)C(O)=O.CC(C)C[C@H](N)C(O)=O YWEKFRWGKMPCEU-MDTVQASCSA-N 0.000 claims description 3
229920001542 oligosaccharide Polymers 0.000 claims description 3
150000002482 oligosaccharides Chemical class 0.000 claims description 3
BKKWZCSSYWYNDS-JEDNCBNOSA-N 2-aminoacetic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCC(O)=O.NCCCC[C@H](N)C(O)=O BKKWZCSSYWYNDS-JEDNCBNOSA-N 0.000 claims description 2
QGTPORGEFWYTOC-MDTVQASCSA-N 2-aminoacetic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCC(O)=O.NCCCC[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O QGTPORGEFWYTOC-MDTVQASCSA-N 0.000 claims description 2
DGRZRONVAUBBJY-NAWJVIAPSA-N 2-aminoacetic acid;(2s)-2-amino-3-(1h-indol-3-yl)propanoic acid Chemical compound NCC(O)=O.C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1.C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 DGRZRONVAUBBJY-NAWJVIAPSA-N 0.000 claims description 2
HVBRJSWZFSWZKB-FVGYRXGTSA-N 2-aminoacetic acid;(2s)-2-amino-3-(1h-indol-3-yl)propanoic acid Chemical compound NCC(O)=O.C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 HVBRJSWZFSWZKB-FVGYRXGTSA-N 0.000 claims description 2
NYOGGQBMEGUVIX-WCCKRBBISA-N 2-aminoacetic acid;(2s)-2-amino-3-methylbutanoic acid Chemical compound NCC(O)=O.CC(C)[C@H](N)C(O)=O NYOGGQBMEGUVIX-WCCKRBBISA-N 0.000 claims description 2
DQSIXGDDUJJEQH-QRPNPIFTSA-N 2-aminoacetic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound NCC(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 DQSIXGDDUJJEQH-QRPNPIFTSA-N 0.000 claims description 2
AYORUWNJMKYNAD-JEDNCBNOSA-N 2-aminoacetic acid;(2s)-2-amino-4-methylpentanoic acid Chemical compound NCC(O)=O.CC(C)C[C@H](N)C(O)=O AYORUWNJMKYNAD-JEDNCBNOSA-N 0.000 claims description 2
FSSVRLXFJPQUTM-WCCKRBBISA-N 2-aminoacetic acid;(2s)-2-amino-4-methylsulfanylbutanoic acid Chemical compound NCC(O)=O.CSCC[C@H](N)C(O)=O FSSVRLXFJPQUTM-WCCKRBBISA-N 0.000 claims description 2
IDFKSUXUURJYNF-SCGRZTRASA-N 2-aminoacetic acid;(2s)-2-amino-4-methylsulfanylbutanoic acid Chemical compound NCC(O)=O.CSCC[C@H](N)C(O)=O.CSCC[C@H](N)C(O)=O IDFKSUXUURJYNF-SCGRZTRASA-N 0.000 claims description 2
UQFMAFYDEDQTCV-PZXRSRGQSA-N 2-aminoacetic acid;(2s,3r)-2-amino-3-hydroxybutanoic acid Chemical compound NCC(O)=O.C[C@@H](O)[C@H](N)C(O)=O.C[C@@H](O)[C@H](N)C(O)=O UQFMAFYDEDQTCV-PZXRSRGQSA-N 0.000 claims description 2
XGKCWNGHLZXLTK-MUWMCQJSSA-N 2-aminoacetic acid;(2s,3r)-2-amino-3-hydroxybutanoic acid Chemical compound NCC(O)=O.C[C@@H](O)[C@H](N)C(O)=O XGKCWNGHLZXLTK-MUWMCQJSSA-N 0.000 claims description 2
MNQVNFIVCSQNGY-FHAQVOQBSA-N 2-aminoacetic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound NCC(O)=O.CC[C@H](C)[C@H](N)C(O)=O MNQVNFIVCSQNGY-FHAQVOQBSA-N 0.000 claims description 2
239000004471 Glycine Substances 0.000 claims description 2
239000008151 electrolyte solution Substances 0.000 claims description 2
235000015097 nutrients Nutrition 0.000 claims description 2
XDDMZVMWZMSAMX-JHNJPSDUSA-N (2s,3s)-2-azanyl-3-methyl-pentanoic acid Chemical compound CC[C@H](C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O XDDMZVMWZMSAMX-JHNJPSDUSA-N 0.000 claims 1
HQEQLJHXFBKKEN-SCGRZTRASA-N 2-aminoacetic acid;(2s)-2-amino-3-methylbutanoic acid Chemical compound NCC(O)=O.CC(C)[C@H](N)C(O)=O.CC(C)[C@H](N)C(O)=O HQEQLJHXFBKKEN-SCGRZTRASA-N 0.000 claims 1
239000000243 solution Substances 0.000 description 20
235000001014 amino acid Nutrition 0.000 description 18
229940024606 amino acid Drugs 0.000 description 18
150000001413 amino acids Chemical class 0.000 description 18
230000032258 transport Effects 0.000 description 7
238000000034 method Methods 0.000 description 5
238000001990 intravenous administration Methods 0.000 description 4
210000004027 cell Anatomy 0.000 description 3
230000000694 effects Effects 0.000 description 3
238000010253 intravenous injection Methods 0.000 description 3
102000004196 processed proteins & peptides Human genes 0.000 description 3
108090000765 processed proteins & peptides Proteins 0.000 description 3
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
206010020772 Hypertension Diseases 0.000 description 2
210000000170 cell membrane Anatomy 0.000 description 2
230000037213 diet Effects 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000007062 hydrolysis Effects 0.000 description 2
238000006460 hydrolysis reaction Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
235000016236 parenteral nutrition Nutrition 0.000 description 2
239000003182 parenteral nutrition solution Substances 0.000 description 2
235000018102 proteins Nutrition 0.000 description 2
102000004169 proteins and genes Human genes 0.000 description 2
108090000623 proteins and genes Proteins 0.000 description 2
210000000813 small intestine Anatomy 0.000 description 2
239000004474 valine Substances 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
KZNQNBZMBZJQJO-UHFFFAOYSA-N 1-(2-azaniumylacetyl)pyrrolidine-2-carboxylate Chemical compound NCC(=O)N1CCCC1C(O)=O KZNQNBZMBZJQJO-UHFFFAOYSA-N 0.000 description 1
JPPZWICGMJJBIH-JEDNCBNOSA-N 2-aminoacetic acid;(2s)-2-amino-3-(1h-imidazol-5-yl)propanoic acid Chemical compound NCC(O)=O.OC(=O)[C@@H](N)CC1=CNC=N1 JPPZWICGMJJBIH-JEDNCBNOSA-N 0.000 description 1
CQBYLZOLQTWVOB-QXGOIDDHSA-N 2-aminoacetic acid;(2s)-2-amino-3-phenylpropanoic acid Chemical compound NCC(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1.OC(=O)[C@@H](N)CC1=CC=CC=C1 CQBYLZOLQTWVOB-QXGOIDDHSA-N 0.000 description 1
IVNJKQPHHPMONX-WCCKRBBISA-N 2-aminoacetic acid;(2s)-2-amino-5-(diaminomethylideneamino)pentanoic acid Chemical compound NCC(O)=O.OC(=O)[C@@H](N)CCCNC(N)=N IVNJKQPHHPMONX-WCCKRBBISA-N 0.000 description 1
ZEEYNQNRMIBLMK-DFWYDOINSA-N 2-aminoacetic acid;(2s)-2-aminopentanedioic acid Chemical compound NCC(O)=O.OC(=O)[C@@H](N)CCC(O)=O ZEEYNQNRMIBLMK-DFWYDOINSA-N 0.000 description 1
FZEBFTHYHFLHGE-WFGSYIHQSA-N 2-aminoacetic acid;(2s,3s)-2-amino-3-methylpentanoic acid Chemical compound NCC(O)=O.CC[C@H](C)[C@H](N)C(O)=O.CC[C@H](C)[C@H](N)C(O)=O FZEBFTHYHFLHGE-WFGSYIHQSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
206010010071 Coma Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
239000004473 Threonine Substances 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
206010047249 Venous thrombosis Diseases 0.000 description 1
TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
238000010521 absorption reaction Methods 0.000 description 1
230000002411 adverse Effects 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
235000009697 arginine Nutrition 0.000 description 1
-1 carbohydrate alcohols Chemical class 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000018044 dehydration Effects 0.000 description 1
238000006297 dehydration reaction Methods 0.000 description 1
210000002249 digestive system Anatomy 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
235000020774 essential nutrients Nutrition 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000014105 formulated food Nutrition 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
210000001035 gastrointestinal tract Anatomy 0.000 description 1
235000013922 glutamic acid Nutrition 0.000 description 1
239000004220 glutamic acid Substances 0.000 description 1
235000014304 histidine Nutrition 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
239000000819 hypertonic solution Substances 0.000 description 1
229940021223 hypertonic solution Drugs 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
230000003914 insulin secretion Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
239000000463 material Substances 0.000 description 1
HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
229930182817 methionine Natural products 0.000 description 1
150000002772 monosaccharides Chemical class 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
230000035764 nutrition Effects 0.000 description 1
235000006180 nutrition needs Nutrition 0.000 description 1
235000020939 nutritional additive Nutrition 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
235000013930 proline Nutrition 0.000 description 1
235000019833 protease Nutrition 0.000 description 1
210000005084 renal tissue Anatomy 0.000 description 1
239000000523 sample Substances 0.000 description 1
230000028327 secretion Effects 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
235000021476 total parenteral nutrition Nutrition 0.000 description 1
HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
239000000811 xylitol Substances 0.000 description 1
229960002675 xylitol Drugs 0.000 description 1
235000010447 xylitol Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates

Landscapes

Life Sciences & Earth Sciences (AREA)
Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Mycology (AREA)
Nutrition Science (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Food Science & Technology (AREA)
Polymers & Plastics (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Medicinal Preparation (AREA)

SE8101585A 1980-03-14 1981-03-12 Neringskomposition som utgor en vattenlosning innehallande fran 1 till 20 viktprocent av minst tva oligopeptider, valda bland dipeptider och tripeptider SE454746B (sv)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US13030980A	1980-03-14	1980-03-14
US06/227,127 US4340592A (en)	1980-03-14	1981-01-26	Nutrient compositions and method of administering the same

Publications (2)

Publication Number	Publication Date
SE8101585L SE8101585L (sv)	1981-09-15
SE454746B true SE454746B (sv)	1988-05-30

Family

ID=26828352

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE8101585A SE454746B (sv)	1980-03-14	1981-03-12	Neringskomposition som utgor en vattenlosning innehallande fran 1 till 20 viktprocent av minst tva oligopeptider, valda bland dipeptider och tripeptider

Country Status (9)

Country	Link
US (1)	US4340592A (de)
AT (1)	AT372281B (de)
AU (1)	AU543401B2 (de)
CH (1)	CH646874A5 (de)
DE (1)	DE3108079C2 (de)
FR (1)	FR2477843A1 (de)
GB (1)	GB2071670B (de)
NL (1)	NL190951C (de)
SE (1)	SE454746B (de)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3206784C2 (de) *	1982-02-25	1985-05-09	Pfrimmer & Co Pharmazeutische Werke Erlangen Gmbh, 8520 Erlangen	Glutaminhaltige Zubereitungen für orale oder intravenöse Applikation
EP0174979A4 (de) *	1984-03-01	1987-11-23	Vernon Erk	Verfahren zur senkung des blutzuckerspiegels bei wirbeltieren.
EP0174957A4 (de) *	1984-03-01	1987-11-09	Vernon Erk	Behandlung von gedächtnisstörungen bei älteren menschen.
EP0175714A4 (de) *	1984-03-01	1987-11-09	Vernon Erk	Behandlungsverfahren von hypoglycemia bei wirbeltieren.
AU578456B2 (en) *	1984-03-01	1988-10-27	Vernon Erk	Tryptophans & manganese treats hypertension and toxemia of pregancy
CA1257806A (en) *	1984-11-19	1989-07-25	Siamak A. Adibi	Nutrient compositions
US5034377A (en) *	1984-11-19	1991-07-23	Montefiore Hospital Association Of Western Pennsylvania	Aqueous nutrient compositions comprising oligopeptides
JPS62149619A (ja) *	1985-09-05	1987-07-03	Teijin Ltd	活性型ビタミンｄ３類注射用組成物
DE3601398A1 (de) *	1986-01-18	1987-07-23	Fresenius Ag	Verwendung von oligopeptiden zur behandlung von cerebralen stoerungen
DE68905387T2 (de) *	1988-06-22	1993-10-21	Ajinomoto Kk	Aminosäure-Nahrungsmittelzusammensetzungen.
DE68910126T2 (de) *	1989-03-28	1994-03-31	Kyowa Hakko Kogyo Kk	Nahrungsmittelzusammensetzung.
US5576351A (en) *	1989-12-29	1996-11-19	Mcgaw, Inc.	Use of arginine as an immunostimulator
US5189016A (en) *	1990-05-18	1993-02-23	Clintec Nutrition Co.	Nutrient compositions containing peptides and method for administering the same
US5122515A (en) *	1990-06-19	1992-06-16	Smith Ross C	Nutrient composition containing dipeptides and method for administering the same
DE4022267C2 (de) *	1990-07-12	1994-09-15	Degussa	N-Acyldipeptide und deren Verwendung
US5167957A (en) *	1990-09-06	1992-12-01	Virginia Tech Intellectual Properties, Inc.	Compositions and methods for the treatment of dietary deficiencies
DE69331528T2 (de) *	1992-12-23	2002-10-31	Abbott Laboratories, Abbott Park	Medizinische nahrungsmittel für die ernährungsergänzung bei metabolischen erkrankungen von säuglingen/kleinkindern
US5326569A (en) *	1992-12-23	1994-07-05	Abbott Laboratories	Medical foods for the nutritional support of child/adult metabolic diseases
JPH06227974A (ja) *	1993-01-29	1994-08-16	Kyowa Hakko Kogyo Co Ltd	栄養組成物
US5891459A (en)	1993-06-11	1999-04-06	The Board Of Trustees Of The Leland Stanford Junior University	Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US5378722A (en) *	1993-12-03	1995-01-03	Clintec Nutrition Co.	Nutritional compositions for management of nitrogen metabolism
US20050196470A9 (en) *	1998-04-03	2005-09-08	Wuh Hank C	Method and composition for enhancing sexual desire
US7371415B1 (en)	1998-04-03	2008-05-13	The Daily Wellness Company	Method and composition for improving sexual fitness
WO1999051252A1 (en) *	1998-04-03	1999-10-14	The Daily Wellness Company	Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
US6605115B1 (en) *	1999-06-05	2003-08-12	Board Of Trustees Of The Leland Stanford Junior University	Method and composition for inhibiting cardiovascular cell proliferation
US7855181B2 (en) *	1999-08-13	2010-12-21	University Of Florida Research Foundation, Inc.	Dipeptides for prevention of muscle breakdown and microbial infection
US6989164B2 (en)	2000-12-22	2006-01-24	The Daily Wellness Company	Method and composition for improving male fertility health
US6497885B2 (en)	2000-12-22	2002-12-24	The Daily Wellness Company	Method and composition for improving fertility health in female and male animals and humans
HRP20040784A2 (en) *	2002-01-29	2005-04-30	Wyeth	Compositions and methods for modulating connexin hemichannels
US20060229256A1 (en) *	2003-09-26	2006-10-12	Bristol-Myers Squibb Company	Enternal administration of arginine and glutamine for abnormal vascular proliferation
WO2005030243A1 (en) *	2003-09-26	2005-04-07	Bristol Myers Squibb Company	Arginyl-glutamine dipeptide for treatment of pathological vascular proliferation
CA2557814A1 (en) *	2004-03-01	2005-09-15	Lumen Therapeutics, Llc	Compositions and methods for treating diseases
JP5198065B2 (ja) *	2005-09-20	2013-05-15	協和発酵バイオ株式会社	ジペプチド含有経口用組成物
EP1957066A4 (de)	2005-11-11	2013-08-28	V Ravi Chandran	Acetylierte aminosäuren als thrombozytenaggregationshemmer, nahrungs- und vitamin-ergänzungsmittel
CA2649842C (en) *	2006-04-21	2015-02-17	Meiji Seika Kaisha, Ltd.	Composition containing peptide as active ingredient
JP4964957B2 (ja) *	2006-09-12	2012-07-04	エフ．ホフマン−ラロシュアーゲー	抗薬物抗体アッセイ
US8257938B2 (en) *	2009-02-27	2012-09-04	Medical Diagnostic Laboratories, Llc	Hemolysin and its protein fragments in sero-detection of Anaplasma phagocytophilum
CN107744140A (zh) *	2017-11-06	2018-03-02	威海红印食品科技有限公司	一种预消化型全营养液及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CH591918A5 (de) *	1974-03-05	1977-10-14	Nestle Sa
CH594367A5 (de) *	1974-05-17	1978-01-13	Brenner Beat Max
US4024286A (en) *	1976-05-17	1977-05-17	Miles Laboratories, Inc.	Fortification of foodstuffs with C-terminal amino acid substituted methionine dipeptides
US4127534A (en) *	1977-06-16	1978-11-28	Coy David Howard	Novel tripeptides, intermediates therefor and pharmaceutical compositions and methods employing said tripeptides

1981
- 1981-01-26 US US06/227,127 patent/US4340592A/en not_active Expired - Lifetime
- 1981-03-03 GB GB8106648A patent/GB2071670B/en not_active Expired
- 1981-03-04 DE DE3108079A patent/DE3108079C2/de not_active Expired
- 1981-03-04 FR FR8104278A patent/FR2477843A1/fr active Granted
- 1981-03-09 CH CH160081A patent/CH646874A5/de not_active IP Right Cessation
- 1981-03-11 NL NL8101182A patent/NL190951C/xx not_active IP Right Cessation
- 1981-03-12 SE SE8101585A patent/SE454746B/sv not_active IP Right Cessation
- 1981-03-13 AU AU68338/81A patent/AU543401B2/en not_active Ceased
- 1981-03-13 AT AT0117581A patent/AT372281B/de not_active IP Right Cessation

Also Published As

Publication number	Publication date
US4340592A (en)	1982-07-20
GB2071670B (en)	1983-07-13
AU6833881A (en)	1981-09-17
AU543401B2 (en)	1985-04-18
ATA117581A (de)	1983-02-15
AT372281B (de)	1983-09-26
FR2477843A1 (fr)	1981-09-18
FR2477843B1 (de)	1985-03-22
NL190951C (nl)	1994-11-16
DE3108079A1 (de)	1982-01-21
DE3108079C2 (de)	1986-01-16
CH646874A5 (de)	1984-12-28
GB2071670A (en)	1981-09-23
NL8101182A (nl)	1981-10-01
SE8101585L (sv)	1981-09-15
NL190951B (nl)	1994-06-16

Legal Events

Date	Code	Title	Description
1995-01-31	NAL	Patent in force	Ref document number: 8101585-1 Format of ref document f/p: F
1996-06-17	SPCF	Application for supplementary protection certificate filed	Free format text: 9690012, 951122
1997-11-24	SPCG	Supplementary protection certificate granted	Free format text: 9690012, 951122, EXPIRES: 20060312
2001-05-21	NUG	Patent has lapsed	Ref document number: 8101585-1 Format of ref document f/p: F

Publication	Publication Date	Title
SE454746B (sv)	1988-05-30	Neringskomposition som utgor en vattenlosning innehallande fran 1 till 20 viktprocent av minst tva oligopeptider, valda bland dipeptider och tripeptider
JP2644086B2 (ja)	1997-08-25	外傷及び外科患者のための栄養製剤
US5889040A (en)	1999-03-30	Composition for increasing protein concentration in a mammal
EP2351491B1 (de)	2015-06-03	Ernährung aus konzentrierter flüssigkeit
US5756481A (en)	1998-05-26	Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction in animals and man
JPH09512552A (ja)	1997-12-16	腎疾患および不全の治療方法ならびに組成物
JPH07507327A (ja)	1995-08-10	神経系損傷を有するヒトのための栄養製剤
US5189016A (en)	1993-02-23	Nutrient compositions containing peptides and method for administering the same
Naylor	1999	Oral electrolyte therapy
Heird	1977	Feeding the premature infant: human milk or an artificial formula?
WO1982003329A1 (en)	1982-10-14	Glucose polymers and method of producing same
EP0666739A1 (de)	1995-08-16	Intravenöse Lösung, die den Prpteinverlust im Körper reduziert
CA2134380C (en)	2010-06-22	Composition based on amino acids intended for the treatment of sepsis or of an attack bringing about an inflammatory reaction, in animals and man
Madden et al.	1940	BLOOD PLASMA PROTEIN PRODUCTION AND UTILIZATION: The Influence of Amino Acids and of Sterile Abscesses
JP5192108B2 (ja)	2013-05-08	反芻動物用のメタン生成抑制用組成物及び飼料用組成物
IT7353266A1 (it)	1975-04-22	Dl-metionil-dl-metionina, procedimento per la sua preparazione ed impiego come additivo per prodotti alimentari e mangimi
Rollins et al.	1990	Three‐in‐one parenteral nutrition: a safe and economical method of nutritional support for infants
JPS6326733B2 (de)	1988-05-31
JPS5923291B2 (ja)	1984-06-01	アミノ酸および無機塩を含有する注入液
Børresen	1972	Balanced intravenous nutrition in pediatric surgery
Johnston	1972	The role of parenteral nutrition in surgical care
SE442480B (sv)	1986-01-13	Forfarande for framstellning av en glukoshaltig infusionslosning
STORER	1960	Fat emulsions for clinical intravenous therapy
KR20240074320A (ko)	2024-05-28	가축 사료첨가용 항산화 조성물 및 이를 포함하는 가축 사료
MacDonald et al.	1993	Influence of dietary fat quantity and composition on insulin binding to rat intestine.